Glenmark Receives U.S. FDA EIR with VAI Status for Goa Facility
Glenmark Pharmaceuticals Ltd 路 Press Release 路 23 Sept 2026, 2:16 pm
Glenmark Receives U.S. FDA EIR with VAI Status for Goa Facility Glenmark Pharmaceuticals Ltd announced on 23rd Sep'26 that it received the Establishment Inspection Report (EIR) from the U.S. FDA for its formulations manufacturing facility in Goa, India. The regulator classified the inspection outcome as Voluntary Action Indicated (VAI), successfully closing the audit conducted between 22nd Jun'26 and 30th Jun'26.
Original exchange filing (PDF)
More announcements from Glenmark Pharmaceuticals Ltd
- Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301 路 18 Nov 2026
- Glenmark Pharmaceuticals Inc., USA Launches Authorised Generic of INLYTA (axitinib) Tablets, 1 mg and 5mg 路 16 Nov 2026
- Schedule of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Initmation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst / Institutional Investor Meetings 路 10 Nov 2026
- Transcript of the Earnings Call 路 09 Nov 2026
- Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 路 06 Nov 2026
